With so many disciplines involved, what unique training and background should be required for clinical molecular imagers?
Have tangible strides been made in using PET scanning to study brain receptor occupancy? Has the tool helped make dosage decisions easier in trials for Alzheimer’s and other CNS drugs?
What are the chief concerns regulators have regarding the use of data from independent imaging assessment committees in helping make endpoint decisions in oncology trials?
What are the one or two, in your opinion, most promising novel imaging techniques emerging in Phase I and II studies, and which therapeutic areas do they have the greatest potential?